Dementia and Alzheimer Disease

Here's what is coming soon to NeurologyLive.

The director of Montefiore Hudson Valley Center of Excellence for Alzheimer’s Disease, associate professor of neurology, Albert Einstein College of Medicine, discussed recent developments in Alzheimer disease research, including FDA approval of aducanumab, as well as the importance of engaging community-based organizations to improve patient care.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 23, 2021.

Alfred Sandrock, MD, PhD, head of research and development, Biogen, has published an open letter to the Alzheimer community in an attempt to clarify “misinformation and misunderstanding” that has moved “outside the boundaries of legitimate scientific deliberation.”

The director of the Montefiore Hudson Valley Center of Excellence for Alzheimer’s Disease commented on social determinants of health in relation to telemedicine and community willingness to engage.

The Integrated Cognitive Assessment showed convergent validity with both MoCA and ACE and offers potential for remote measurement of cognitive performance in Alzheimer disease and mild cognitive impairment.

In Alzheimer disease and dementia, Jessica Zwerling, MD, MS, director, Montefiore Hudson Valley Center of Excellence for Alzheimer’s Disease, believes normalizing trial recruitment aids and telehealth to increase participation is another way to ease delivery of care.

The study data suggest that intervention strategies to improve antimicrobial and burdensome intervention for suspected LRIs and UTIs are ineffective.

Challenges surrounding the use of telehealth for patients with Alzheimer disease are affected by technological barriers, according to the associate director of the Montefiore Hudson Valley Center of Excellence for Alzheimer’s Disease

The director of the Montefiore Hudson Valley Center of Excellence for Alzheimer’s Disease discusses the use of telehealth for patients with Alzheimer disease during the COVID-19 pandemic, as well as her thoughts on why it is here to stay.

Here's what is coming soon to NeurologyLive.

Jessica Zwerling, MD, associate director, Center for the Aging Brain, Montefiore Medical Center, discussed the impact that telemedicine has had in Alzheimer and dementia care.

Neurology News Network for the week ending July 17, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 15, 2021.

Investigators found that certain underrepresented communities were less likely to be eligible for Alzheimer disease trials after the first screening visit.

The position statement considers the diagnosis of dementia, problems in decision making, symptoms and behavioral management, and the relationship between dementia care and society.

The observational study, initiated by Centogene in partnership with Alector, aims to identify and explore the frequency of genetic mutations in patients with frontotemporal dementia.

ATH-1017, an investigational agent designed to focus on network recovery and synaptic signal transition in the brain, will be evaluated in patients on cognition, global, and functional assessments.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 9, 2021.

Janet Woodcock, MD, acting commissioner of the FDA, called for an inquiry by the Office of the Inspector General into possible interactions between agency officials and Biogen that "may have occurred outside of the formal correspondence process."

Since 2016, there has been consistent growth in the number of Alzheimer disease trials sponsored both in part and fully by academic medical centers and/or the National Institutes of Health.

The newly updated label language emphasizes the Alzheimer disease stages in which aducanumab was studied, with no additional changes made to its approval pathway.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 2, 2021.

ICER’s health-benefit price benchmark range for aducanumab is $3000 to $8400 per year for patients with early Alzheimer disease, substantially lower than the current $56,000 annual price listing.

Both high PiB and low entorhinal fluorodeoxyglucose as inclusion criteria reduced 3-fold the number of participants needed in a hypothetical trial compared to using only high PiB.

Patients who received high-dose blarcamesine experienced a 14.51-point MDS-UPDRS total score improvement compared to placebo in a phase 2 study of the Anavex Life Sciences agent.

Clive Ballard, MD, discussed up-and-coming technologies for remote risk assessment, among other data presented at this year’s AAIC meeting.

Hermona Soreq, PhD, discusses the complexities of aducanumab’s FDA approval, her initial reaction to the news, and whether it might be greenlit by other country’s regulators.